"Cyclic Nucleotide Phosphodiesterases, Type 5/metabolism"[MAJR] - Search Results

Year	Number of Results
2006	2
2007	10
2008	21
2009	19
2010	19
2011	27
2012	29
2013	21
2014	23
2015	21
2016	8
2017	18
2018	22
2019	22
2020	19
2021	16
2022	1
2023	1
2024	3

1

Cardiac Phosphodiesterases and Their Modulation for Treating Heart Disease.

Kim GE, Kass DA. Kim GE, et al. Handb Exp Pharmacol. 2017;243:249-269. doi: 10.1007/164_2016_82. Handb Exp Pharmacol. 2017. PMID: 27787716 Free PMC article. Review.

2

Phosphodiesterase type 5 (PDE5) in the adipocyte: a novel player in fat metabolism?

Armani A, Marzolla V, Rosano GM, Fabbri A, Caprio M. Armani A, et al. Trends Endocrinol Metab. 2011 Oct;22(10):404-11. doi: 10.1016/j.tem.2011.05.004. Epub 2011 Jul 7. Trends Endocrinol Metab. 2011. PMID: 21741267 Review.

3

Type 5 phosphodiesterase (PDE5) and the vascular tree: From embryogenesis to aging and disease.

Cesarini V, Guida E, Campolo F, Crescioli C, Di Baldassarre A, Pisano C, Balistreri CR, Ruvolo G, Jannini EA, Dolci S. Cesarini V, et al. Mech Ageing Dev. 2020 Sep;190:111311. doi: 10.1016/j.mad.2020.111311. Epub 2020 Jul 3. Mech Ageing Dev. 2020. PMID: 32628940 Free PMC article. Review.

4

Role of Phosphodiesterase 5 and Cyclic GMP in Hypertension.

Mergia E, Stegbauer J. Mergia E, et al. Curr Hypertens Rep. 2016 Apr;18(5):39. doi: 10.1007/s11906-016-0646-5. Curr Hypertens Rep. 2016. PMID: 27079836 Free PMC article. Review.

5

Reno-protective effects of Phosphodiesterase 5 inhibitors.

Coskuner ER, Ozkan B. Coskuner ER, et al. Clin Exp Nephrol. 2021 Jun;25(6):585-597. doi: 10.1007/s10157-021-02051-6. Epub 2021 Mar 22. Clin Exp Nephrol. 2021. PMID: 33754203 Review.

6

Cardiac role of cyclic-GMP hydrolyzing phosphodiesterase type 5: from experimental models to clinical trials.

Kass DA. Kass DA. Curr Heart Fail Rep. 2012 Sep;9(3):192-9. doi: 10.1007/s11897-012-0101-0. Curr Heart Fail Rep. 2012. PMID: 22798047 Free PMC article. Review.

7

Cellular Redox Metabolism Is Modulated by the Distinct Localization of Cyclic Nucleotide Phosphodiesterase 5A Isoforms.

Cardarelli S, Miele AE, Campolo F, Massimi M, Mancini P, Biagioni S, Naro F, Giorgi M, Saliola M. Cardarelli S, et al. Int J Mol Sci. 2022 Aug 2;23(15):8587. doi: 10.3390/ijms23158587. Int J Mol Sci. 2022. PMID: 35955722 Free PMC article.

8

PDE5 inhibitors beyond erectile dysfunction.

Sandner P, Hütter J, Tinel H, Ziegelbauer K, Bischoff E. Sandner P, et al. Int J Impot Res. 2007 Nov-Dec;19(6):533-43. doi: 10.1038/sj.ijir.3901577. Epub 2007 Jul 12. Int J Impot Res. 2007. PMID: 17625575 Review.

9

Phosphodiesterase 5 (PDE5): Structure-function regulation and therapeutic applications of inhibitors.

Ahmed WS, Geethakumari AM, Biswas KH. Ahmed WS, et al. Biomed Pharmacother. 2021 Feb;134:111128. doi: 10.1016/j.biopha.2020.111128. Epub 2020 Dec 18. Biomed Pharmacother. 2021. PMID: 33348311 Free article. Review.

10

Phosphodiesterase type 5 regulation in the penile corpora cavernosa.

Lin CS. Lin CS. J Sex Med. 2009 Mar;6 Suppl 3:203-9. doi: 10.1111/j.1743-6109.2008.01179.x. J Sex Med. 2009. PMID: 19267844 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

249 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

249 results

Results by year